Nanobiotix is transforming into a capital-light oncology platform focused on milestone and royalty revenues, centered on its JNJ-1900 program now led by Johnson & Johnson. JNJ-1900 aims to enhance radiotherapy across multiple solid tumors, with a potential $2.6 billion milestone structure and double-digit royalties. Recent financing and a planned equity raise in May 2026 extend Nanobiotix's cash runway through 2029, transferring much clinical and operational risk to J&J. While speculative, Nanobiotix offers upside if its radiotherapy platform gains broad adoption but faces risks including clinical trial outcomes, operational challenges, and dilution from fundraising.
US stock futures are down, led by a 1% drop in the Nasdaq-100, due to escalating tensions in the Middle East. President Trump's threats against Oman and Iran have driven oil prices up to their highest in two weeks, with Brent crude at $91 a barrel. R...
Flagstar Bank faces ongoing challenges with elevated nonperforming assets at 4.60%, significantly above its loan loss allowance of 1.42%, which is hurting its earnings growth. Although recent loan and deposit growth have turned positive, the bank's S...
Greystone Housing's stock has increased nearly 20% following a strategic distribution reset by management, yet it still trades at a significant 46% discount to its $11.20 book value. Management plans to wind down its joint venture equity development ...
Can-Am has introduced its 2027 range of side-by-side vehicles (SSV) and all-terrain vehicles (ATV), featuring the new Defender XU model with utility-focused features and a redesigned Defender HD10 with a triple-cylinder engine. All Maverick R models ...
IBM's stock declined 9% following a sharp 42% drop in mainframe sales in Q2 2026, causing investor concern. Despite this, the stock appears fairly valued rather than a bargain. IBM's growth now relies heavily on its software segment, which makes up 4...
